Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse / Refractory Multiple Myeloma

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse / refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Not Available
Phase I
Adults
Not Available
Not Available
Cornell, Robert
National
Vanderbilt University
12-26-2018
Treatment
VICCHEMP1855
NCT03269136

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Patients with relapse/ refractory multiple myeloma

Performance Status of 0- 2 (unless due to bone pain)

Adequate bone marrow, kidney and liver function



Exclusion Criteria:

History of active autoimmune disorders

Active and clinically significant bacterial, fungal, or viral infection

Major surgery within 4 weeks of study treatment start

Radiation therapy within 2 weeks of study treatment start

Less than 30 days since last dose of anti CD38 therapy, elotuzumab or other anti-CD319 therapy or less than 5 half-lives since last dose of previous systemic therapy.

Stem cell transplant (autologous or allogeneic) within 100 days of study treatment start

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: